Haddad A, Suter M, Greve JW, Shikora S, Prager G, Dayyeh BA, et al
Clinical trials show average outcomes of 15 to 21% body weight loss over 68 weeks depending on the medication, though individual results vary
Evidence for astrocytosis in prodromal Alzheimer disease provided by 11 C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11 C-Pittsburgh compound B and 18 F-FDG
[11] Clinical studies such as the SUSTAIN programme (semaglutide) and AWARD trials (dulaglutide) demonstrate that GLP-1 receptor agonists can reduce HbA1c by approximately 0.81.5% on average, with some patients achieving greater reductions depending on baseline values and adherence
Managing Autoimmune Diseases: Treatment and Lifestyle While many autoimmune diseases are chronic, effective management strategies can help control symptoms and improve quality of life